Drug Trial Radar · NCT04696731
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 24, 2021
Primary completion
Jan 2030
Study completion Jan 2030
Sponsor
- Lead sponsor
- Allogene TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 dose escalation study using a 3+3 study design, followed by a phase 1b expansion study. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, with or without ALLO-647 to define a Phase 2 dose.
Conditions
- Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Interventions
ALLO-316Genetic
ALLO-316 is an allogeneic CAR T cell therapy targeting CD70
ALLO-647Biological
ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
FludarabineDrug
Chemotherapy for lymphodepletion
CyclophosphamideDrug
Chemotherapy for lymphodepletion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-316Time frame: 28 days
- Proportion of patients experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-316Time frame: 33 days
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
UCLA Medical Center
Los Angeles, California
UCSF Medical Center
San Francisco, California
Yale School of Medicine
New Haven, Connecticut
Georgetown University Hospital
Washington D.C., District of Columbia
Moffitt Cancer Center
Tampa, Florida
Karmanos Cancer Institute
Detroit, Michigan
Memorial Sloan Kettering Cancer Center
New York, New York
Providence Portland Medical Center
Portland, Oregon
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.